TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11193130
Drug: Continued medication
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued medication group (C), n = 24
Study: 8473466
Drug: D‐Trp6 LHRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐Trp6 LHRH microcapsules (i.m. injection) at 2 months and 1 month prior to surgery
Study: 8473466
Drug: No pre‐operative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre‐operative treatment (control group)
Study: 3964516
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (0.2 mg)
Study: 3964516
Drug: Intramuscular buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular buprenorphine (0.15 mg)
Study: 3964516
Drug: Both routes
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both routes (sublingual and i.m.)
Study: 8138651
Drug: Intramuscular buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular buprenorphine
Study: 28093466
Drug: Sacubitril/valsartan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan 200 mg
Study: 20015788
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin (LVFX)
Study: 20015788
Drug: Intravenous flomoxef
Normalized name: flomoxef
DrugBank: Flomoxef (DB11935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous flomoxef (FMOX)
Study: 7607735
Drug: Methacholine (nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine (nonselective agonist)
Study: 7607735
Drug: Atropine (nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (nonselective antagonist)
Study: 7607735
Drug: Pirenzepine (M1-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (M1-selective antagonist)
Study: 7607735
Drug: AF-DX 116
Normalized name: Canesten AF
Approvals — FDA: no, EMA: no, PMDA: no
Description: AF-DX 116 (M2-selective antagonist)
Study: 627337
Drug: Indomethacin 3
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 3 X 25 mg orally for 5 days starting 2 days before menstruation
Study: 23446090
Drug: Liposome bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome bupivacaine (66 to 532 mg)
Study: 23446090
Drug: Bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl (75 to 200 mg)
Study: 20854436
Drug: Tomato paste
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato paste (55 g daily, 16 mg lycopene)
Study: 17185999
Drug: Buprenorphine (0.05‐0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.05‐0.6 mg/70 kg)
Study: 17185999
Drug: Fentanyl (0.075‐0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.075‐0.5 mg/70 kg)
Study: 9308614
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of lamotrigine 1 hour before spinal anesthesia
Study: 3555028
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of ciprofloxacin orally every 12 hours for two weeks
Study: 3555028
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of ciprofloxacin orally every 12 hours for two weeks
Study: 27218285
Drug: Pimpinella anisum‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimpinella anisum‐based herbal medicine (Sinupim), 2 drops in each nostril every 12 hours for 4 weeks
Study: 27218285
Drug: Fluticasone nasal
Normalized name: fluticasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone nasal spray, 2 puffs in each nostril every 12 hours for 4 weeks
Study: 24691094
Drug: Evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 140 mg biweekly
Study: 21166990
Drug: Mandibular two-implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular two-implant overdentures with different attachment systems
Study: 12956494
Drug: Mandibular two-implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular two-implant overdentures
Study: 17095130
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of hepatitis B vaccine
Study: 17095130
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of hepatitis B vaccine
Study: 16298778
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and placebo light treatment
Study: 16298778
Drug: Light treatment
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light treatment and placebo pill
Study: 11991015
Drug: Shellyquine (plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shellyquine (plain formulation)
Study: 11991015
Drug: Dawaquin (sugar-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dawaquin (sugar-coated formulation)
Study: 2339797
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of warm lidocaine (40.6 +/‐ 0.7 degrees C)
Study: 2339797
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of cold lidocaine (16.0 +/‐ 4.7 degrees C)
Study: 26109120
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow (HF) therapy
Study: 23689263
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Zn as zinc sulfate, daily for 21 days
Study: 23689263
Drug: Placebo, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, daily for 21 days
Study: 19159453
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Omega-3 fatty acids
Study: 19159453
Drug: Placebo (Aspirin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Aspirin)
Study: 19159453
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Omega-3 fatty acids placebo
Study: 19159453
Drug: Aspirin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin placebo and Omega-3 fatty acids
Study: 17653751
Drug: triamcinolone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: triamcinolone (4 mg) injection
Study: 9772056
Drug: Modified triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified triple therapy (PCM): 40 mg pantoprazole b.i.d., 500 mg clarithromycin t.i.d., and 500 mg metronidazole t.i.d. for 7 days; followed by 40 mg pantoprazole o.d. until day 28.
Study: 9772056
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (PC): 40 mg pantoprazole b.i.d. and 500 mg clarithromycin t.i.d. for 14 days; followed by 40 mg pantoprazole o.d. until day 28.
Study: 3973786
Drug: Short-term prophylaxis
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term prophylaxis with rectally administered diazepam for 18 months, mean of five doses per child per year
Study: 3973786
Drug: Short-term prophylaxis
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term prophylaxis with rectally administered diazepam for 18 months
Study: 29912425
Drug: SCFP at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCFP at 14 g·steer‐1·d‐1
Study: 29912425
Drug: SCFP at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCFP at 0 g·steer‐1·d‐1 (Control)
Study: 29912425
Drug: SCFP at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCFP at 28 g·steer‐1·d‐1
Study: 25787121
Drug: 1% metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% metformin gel with scaling and root planing (SRP)
Study: 25201648
Drug: Feeling Better
Normalized name: BITTER ORANGE PEEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feeling Better intervention (Cognitive Behavioural Therapy programme)
Study: 21911258
Drug: Adjunctive oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive oral S-adenosylmethionine (SAMe)
Study: 15061293
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg oral ramosetron
Study: 15061293
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg intravenous ramosetron
Study: 24152567
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg twice daily (Triple)
Study: 24152567
Drug: Clopidogrel 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 150 mg daily (Double)
Study: 17377212
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/day within 24 hours after stroke onset (Group I, n = 18)
Study: 14687744
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens 0.625 mg combined with medroxyprogesterone acetate 5 mg (CEE/MPA, n=31)
Study: 14687744
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg (n=42)
Study: 8483562
Drug: MMM (mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMM (mitomycin 7‐8 mg/m2 i.v. every 6 weeks; mitoxantrone 7‐8 mg/m2 i.v. every 3 weeks; methotrexate 35 mg/m2 i.v. every 3 weeks)
Study: 8483562
Drug: VAC (vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC (vincristine 1.4 mg/m2 every 3 weeks, anthracycline 30 mg/m2 every 3 weeks, cyclophosphamide 400 mg/m2 every 3 weeks)
Study: 8483562
Drug: CMF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (cyclophosphamide 100 mg orally, days 1‐14; methotrexate 35 mg/m2 i.v. days 1 and 8; 5‐fluorouracil 1 g i.v. days 1 and 8)
Study: 30067323
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of botulinum toxin A
Study: 21040375
Drug: Racemic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic ketamine (3 mg kg(‐1))
Study: 21040375
Drug: S-ketamine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (1.5 mg kg(‐1))
Study: 323025
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg physostigmine i.v.
Study: 19299903
Drug: UFT in
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT in combination with oxaliplatin (TEGAFOX)
Study: 19299903
Drug: UFT in
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT in combination with irinotecan (TEGAFIRI)
Study: 14962401
Drug: Invalid preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invalid preparation for the irrelevant task
Study: 14962401
Drug: Invalid preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invalid preparation
Study: 3887870
Drug: PPC (amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPC (amino acid preparation)
Study: 25592006
Drug: Green coffee
Normalized name: Green coffee bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green coffee bean extract (10 mg/kg, 5 mg/kg chlorogenic acid)
Study: 23503735
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (bronchodilators, antibiotics, oxygen, patient education)
Study: 18263663
Drug: Varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1 mg twice daily for 12 weeks)
Study: 18263663
Drug: Transdermal NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal NRT (21 mg/day reducing to 7 mg/day for 10 weeks)
Study: 18263663
Drug: Transdermal NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal NRT
Study: 16426449
Drug: Active Physical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Physical Treatment (APT)
Study: 16426449
Drug: Combined Treatment
Normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Treatment (CT) of APT and CBT
Study: 12483414
Drug: N‐[(11)C‐methyl]‐L‐deuterodeprenyl (DED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐[(11)C‐methyl]‐L‐deuterodeprenyl (DED) imaging
Study: 1468186
Drug: ponalrestat 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ponalrestat 600 mg/day
Study: 29463231
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy adherence assessment
Study: 28606219
Drug: Dietary calcium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary calcium intake (mean 870 mg/d)
Study: 26206258
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with anthracyclines (epirubicin -> cyclophosphamide, methotrexate and fluorouracil (CMF))
Study: 26206258
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without anthracyclines (CMF)
Study: 21441356
Drug: High concurrent
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concurrent self-regulatory efficacy (SRE) group
Study: 21441356
Drug: Low concurrent
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concurrent self-regulatory efficacy (SRE) group
Study: 17335643
Drug: rTMS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS treatment with reduced frequency (from two sessions per day to one)
Study: 17335643
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for TEM (decrease or discontinuation of antidepressant and/or rTMS treatment and/or use of anti-manic medication)
Study: 16996855
Drug: 32 mg
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg candesartan cilexetil
Study: 12790064
Drug: Standard-of-care treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatments for postoperative pain management
Study: 8732473
Drug: Menorest (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menorest (transdermal oestradiol) at doses of 50, 75, 100 micrograms/day in study 201 and 25, 50, 75 micrograms/day in study 305, administered cyclic sequential or continuous sequential with dydrogesterone 20 mg/day during the last 14 days.
Study: 8732473
Drug: Menorest (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menorest (transdermal oestradiol)
Study: 1426355
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 200 mg/d
Study: 1426355
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 1000 mg/d
Study: 6697071
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg Depomedrone in normal saline made up to 20 ml
Study: 6697071
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.25% bupivacaine solution
Study: 6697071
Drug: Needling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needling with a standard Touhy injection needle into the interspinous ligament (no injection)
Study: 28166785
Drug: Initial DMARD-monotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial DMARD-monotherapy (sulfasalazine (SSZ) or methotrexate (MTX))
Study: 28166785
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination MTX/etanercept
Study: 28166785
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Initial DMARD-monotherapy and Initial MTX / prednisolone-bridging)
Study: 25476268
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received a leaflet on preparation instructions
Study: 21355003
Drug: Trastuzumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (8 mg/kg loading dose, 6 mg/kg every 3 weeks for 1 year) plus chemotherapy
Study: 21355003
Drug: Trastuzumab (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (with chemotherapy)
Study: 11758296
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment options for functional dyspepsia
Study: 9532994
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole treatment during pregnancy
Study: 2023417
Drug: Methotrexate 50
Normalized name: methotrexate 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 50 mg/m2 on the 3rd, 10th, and 17th postoperative days
Study: 2642546
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with CCNU and radiation therapy
Study: 31046185
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy including desensitization maneuvers of the central nervous system
Study: 21925959
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review intervention delivered by pharmacists
Study: 19587607
Drug: beta-Blockers
Normalized name: BETA-BLOCKERS,TOPICAL OPHTHALMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-Blockers
Study: 16625984
Drug: Dexibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexibuprofen (400 mg t.i.d for 3 days, then 400 mg b.i.d for 11 days)
Study: 16625984
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg t.i.d for 3 days, then 800 mg b.i.d for 11 days)
Study: 16625984
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg t.i.d for 3 days, then 50 mg b.i.d for 11 days)
Study: 16625984
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Dexibuprofen, Ibuprofen, Diclofenac)
Study: 15630183
Drug: Rosmarinic acid
Normalized name: ROSMARINIC ACID
DrugBank: Rosmarinic acid (DB16865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosmarinic acid (RA) 200 mg or 50 mg
Study: 9205786
Drug: Cefodizime 2
Normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime 2 g once daily (either intravenously or intramuscularly)
Study: 2891372
Drug: 16-phenoxy-W-17, 18,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16-phenoxy-W-17, 18, 19, 20-tetranor PGE2 methyl sulfonylamide (three intramuscular injections of 0.5 mg at 3-h intervals)
Study: 29395279
Drug: OTO‐201 (ciprofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTO‐201 (ciprofloxacin otic suspension 6%) intraoperative injection
Study: 28629473
Drug: Intravenous phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous phenytoin (20 mg/kg, maximum 2 g)
Study: 28629473
Drug: Intravenous levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous levetiracetam (40 mg/kg, maximum 2.5 g)
Study: 20921467
Drug: Concurrent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent therapy (paclitaxel 225 mg/m² and carboplatin AUC 6 every 3 weeks plus cetuximab 400 mg/m² loading dose followed by 250 mg/m² weekly for four cycles)
Study: 20921467
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (paclitaxel-carboplatin for four cycles followed by cetuximab)
Study: 19099714
Drug: Inhaled Nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide (iNO) at 15 ppm for 34.90 ± 16.41 hours
Study: 17213687
Drug: Long-term air-conditioning
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term air-conditioning exposure (L)
Study: 12648193
Drug: Music in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music in combination with therapeutic suggestions (M/TS)
Study: 10922094
Drug: Oral preparation
Normalized name: Iron bivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral preparation (45 mL oral sodium phosphate and 10 mg bisacodyl)
Study: 10922094
Drug: Enema preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enema preparation (2 Fleet enemas and 10 mg bisacodyl)
Study: 8141211
Drug: Amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (500 mg three times daily for 7 days)
Study: 3410567
Drug: Sodium concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium concentration at 139 mmol/l
Study: 21148631
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (SXB) 3 g per night for five consecutive nights
Study: 16816220
Drug: Mirtazapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (up to 60 mg/day)
Study: 16816220
Drug: Nortriptyline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (up to 200 mg/day)
Study: 12705063
Drug: Selective cyclooxygenase‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective cyclooxygenase‐2 inhibitor (celexocib)
Study: 12705063
Drug: Non steroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non steroidal anti‐inflammatory drugs (NSAIDs)
Study: 12705063
Drug: Aspirin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin®
Study: 8527613
Drug: etodolac 300
Normalized name: etodolac 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etodolac 300 mg b.d.
Study: 20495139
Drug: Phenylephrine 50
Normalized name: phenylephrine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 50 μg/min
Study: 31107542
Drug: Dose‐intensified radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose‐intensified radiotherapy plus capecitabine and oxaliplatin (CAPOX50)
Study: 28002167
Drug: Haloperidol 1
Normalized name: haloperidol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 1 mg intravenously